Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 796, Issue 1, 2003, Pages 181-188

  Lepper, Erin R ^a   Swain, Sandra M ^a   Tan, Antoinette R ^a   Figg, William D ^a   Sparreboom, Alex ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Erlotinib; OSI 774; Pharmacokinetics

Indexed keywords

EFFLUENTS; GROWTH KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PATIENT MONITORING; PHARMACOKINETICS; SOLVENT EXTRACTION; TUMORS;

MOBILE PHASE;

BIOMEDICAL ENGINEERING;

ACETONITRILE; AMLODIPINE BESYLATE; ATENOLOL; CHLORIDE; CIPROFLOXACIN; CLOTRIMAZOLE; CYANOCOBALAMIN; DEXAMETHASONE; DIAZEPAM; DIPHENHYDRAMINE; DOCUSATE SODIUM; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; FLUTICASONE PROPIONATE; FOLIC ACID; GLUCOSAMINE SULFATE; HYDROMORPHONE; HYDROXYZINE; KETOCONAZOLE; LEVOFLOXACIN; LEVOTHYROXINE; LOPERAMIDE; METRONIDAZOLE; MORPHINE SULFATE; OMEPRAZOLE; ONDANSETRON; OSI 597; PROTEIN TYROSINE KINASE INHIBITOR; UNINDEXED DRUG; WATER;

ACCURACY; ARTICLE; BREAST CANCER; CALIBRATION; CANCER PATIENT; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DETECTION; RADIATION MONITORING; SOLVENT EXTRACTION; ULTRAVIOLET RADIATION;

BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 1542608473     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2003.08.015     Document Type: Article

References (13)

1. Woodburn J.R. Pharmacol. Ther. 82:1999;241.
2. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Crit. Rev. Oncol. Hematol. 19:1995;183.
3. Grunwald V., Hidalgo M. Curr. Probl. Cancer. 26:2002;109.
4. Schiller J.H. Semin. Oncol. 30:2003;49.
5. Norman P. Curr. Opin. Investig. Drugs. 2:2001;298.
6. Ng S.S., Tsao M.S., Nicklee T., Hedley D.W. Mol. Cancer Ther. 1:2002;777.
7. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A., Vaidya M.P., Arnold L.D., Doty J.L., Iwata K.K., Morin M.J. J. Pharmacol. Exp. Ther. 291:1999;739.
8. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., Eckhardt S.G., Tolcher A., Britten C.D., Denis L., Ferrante K., Von Hoff D.D., Silberman S., Rowinsky E.K. J. Clin. Oncol. 19:2001;3267.
9. Kim T.E., Murren J.R. Curr. Opin. Invest. Drugs. 3:2002;1385.
10. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D.et al. Eur. J. Drug Metab. Pharmacokinet. 16:1991;249.
11. M. Zhao, P. He, M.A. Rudek, M. Hidalgo, S.D. Baker, J. Chromatogr. B 793 (2003) 413.
12. Loos W.J., Verweij J., Nooter K., Stoter G., Sparreboom A. J. Chromatogr. B Biomed. Sci. Appl. 693:1997;437.
13. Hartmann C., Smeyers-Verbeke J., Massart D.L., McDowall R.D. J. Pharm. Biomed. Anal. 17:1998;193.